<DOC>
<DOCNO>
EP-0006718
</DOCNO>
<TEXT>
<DATE>
19800109
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/41 A61P-7/02 C07C-45/51 C07C-41/00 C07C-41/30 C07C-45/00 C07D-249/12 A61P-7/00 A61P-1/00 C07C-29/00 A61P-1/04 C07C-49/255 C07C-29/40 C07C-47/02 C07C-309/00 C07C-43/00 C07C-41/26 C07C-43/12 C07C-43/23 C07D-249/00 C07C-45/30 C07C-49/00 C07C-309/73 A61P-9/00 A61P-9/12 A61P-9/06 C07C-43/178 C07C-45/29 C07C-47/198 <main>C07D-249/12</main> A61P-43/00 
</IPC-CLASSIFICATIONS>
<TITLE>
1.2.4-triazolidine-3.5-dione derivatives, process for their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
beecham group plcgb<sep>beecham group plc<sep>beecham group plcbeecham house, great west roadbrentford, middlesex tw8 9bdgb<sep>beecham group plc<sep>
</APPLICANT>
<INVENTOR>
adams david reginald<sep>barnes allen frank<sep>adams, david reginald<sep>barnes, allen frank<sep>adams, david reginaldc/o faculdad de farmacia universidad centralde venezuela caracasve<sep>barnes, allen frank37 south roadbishops stortford, hertfordshiregb<sep>adams, david reginald<sep>barnes, allen frank<sep>adams, david reginaldc/o faculdad de farmacia universidad centralde venezuela caracasve<sep>barnes, allen frank37 south roadbishops stortford, hertfordshiregb<sep>
</INVENTOR>
<ABSTRACT>
coumpounds of the formula (i)    wherein:   n is 1 to 5   y is -ch₂-ch₂, -ch=ch- or -c≡c-   r₁ is hydrogen or co₂r₁ represents an ester group in  which the r₁ moiety contains from 1-12 carbon atoms;   r₂ is hydrogen, c₁₋₄ alkyl or phenyl;   r₃ is hydroxy or protected hydroxy;   r₄ is a group of the formula:   l-q-r₁₀   in which   q is an oxygen atom, a -ch=ch- group or a -c≡c-  group, and   l is a c₁₋₉ alkylene group; and   r₁₀ is c₁₋₄ alkyl, phenyl or naphthyl, any of which phenyl or  naphthyl moieties may be substituted by one or more halogen,  trifluoromethyl, c₁₋₆ alkyl, hydroxy, c₁₋₆ alkoxy, phenyl c₁₋₆  alkoxy or nitro groups, or if q is a -ch=ch- group, the r₁₀  may be a hydrogen atom; and r₅ is hydrogen or c₁₋₆ alkyl; and  salts thereof, having similar activity to natural prostaglandins, a  process for their preparation, intermediates useful in that pro­ cess and pharmaceutical compositions containing them.  
</ABSTRACT>
<DESCRIPTION>
novel organic compounds this invention relates to novel compounds having pharmacological activity, to a process for their preparation, to intermediates useful in that process. and to pharmaceutical composition containing them offenlegungsschrift no: 2323193 discloses that pyrazolidine derivatives of the formula (i)': wherein: emi1.1 a is ch=ch or chic; r is h, an alkali metal, an amine salt, or a # 12c hydrocarbon or chlorohydrocarbon residue; m is oor 1; n is 0-6; p is 0-6; and y and z are 0 or h except that y and z are not both 0; have similar biological properties to the prostaglandins or are antagonists of prostaglandins. french patent application no: 2258376 discloses that 10-aza prostaglandins of formula (ii)": emi2.1 wherein: r=h or lower alkyl; r' and r" = ch3 or c2h5; r =h or lower alkyl; y = -ch2-ch2-, or -ch = ch-; z = -co or -ch(¯ch)-; are useful in the treatment of blood pressure and gastro-intestinal disorders, and in the preparation for confinement. belgian patent no: 835989 discloses that compounds of the formula (iii)": emi2.2 wherein: x is co, protected co, croh in which r is hydrogen or c14 alkyl and in which the oh moiety may be protected; y is ch2ch2 or ch=ch; z is co or ch2; n is 1 to 8; m is 1, 2 or 3; r1 is hydrogen, ch2oh, ch2oh in which the oh moiety is protected, co2w wherein w is hydrogen or co2w represents an ester group in which the ester moiety contains from 1 to 12 carbon atoms, or conh2; r2 is hydrogen, c1-4 alkyl, or taken together with r3 and the carbon atom t.o which it is attached represents a carbonyl group; r3 is hydrogen, hydroxy or protected hydroxy; r4 is hydrogen or c1 galkyl; and salts thereof; have useful pharmacological activity. a novel class of compounds also having useful pharmacological activity his now been discovered, which compounds are structurally distinct from the prior art referred to above. accordingly the present invention provides a compound of the formula (i): emi3.1 wherein: n is 1 to 5 y is -ch2-ch2, -ch=ch- or -cc- r1 is hydrogen or c02r1 represents an ester group in which the r1 moiety contains from 1-12 carbon atoms; r2 is hydrogen, c1-4 alkyl or phenyl; r3 is hydroxy or protected hydroxy; r4 is a group of the formula: l - q - r10 in which: q is an oxygen atom, a -ch=ch- group or a -c¯c- group, and l is a r alkylene group; and r10 is c1-4 alkyl, phenyl or napnthyl, any of which phenyl or naphthyl moieties may be substituted by one or more halogen, trifluoromethyl, c1 6alkyl, hydroxy, c1-6alkoxy, phenyl c1 6alkoxy or nitro groups, or, if q is a -ch=ch- group, then r10 may be a hydrogen atom; and r5 is hydrogen or c16alkyl; and salts thereof. suitably n is 2, 3 or 4, preferably 3. similarly y may be -ch2-ch2- or -ch=ch-, suitably -ch2-ch2-. r1 is hydrogen, or c02r1 represents an ester group in
</DESCRIPTION>
<CLAIMS>
claims   1. a   compound    of the formula (i): emi49.1        characterised in that:  n is 1 to 5;  y is -ch2-ch2, -ch=ch- or   -c--c-     r1 is hydrogen or c02r1 represents an ester group in which the  r1 moiety contains from 1-12 carbon atoms;  is hydrogen, c1-4 alkyl or phenyl;  r3 is hydroxy or protected hydroxy;  r4 is is a group of the formula:  l - q - r10  in which:  q is an   oxygen    atom, a -ch=ch- group or a -cc- group and  l is a   c1 9    alkylene group;  and r10 is   c1      4    alkyl, phenyl or    nphthyl,    any of which phenyl or naphthyl moieties may be    @bstituted    by one or more halogen, trifluoromethyl, c1-6  alkoxy, phenyl c1-6 alkoxy or nitro groups, or, if q is a    -chl-ch-    group, then r10 may be a hydrogen atom; and   r5    is  hydrogen or c1-6 alkyl; and salts thereof.   2. a compound according to claim 1 of   formula    (ii): emi49.2       characterised in that: y, r1 and r5 are as defined in claim 1: n is 2, 3 or rú 1 is   hydrogen,    methyl, ethyl or phenyl; and r1 is a group of    2    the   formula:         1     10  in which  l is a c1   9   alkylene group; and  rú10 is 1-4 alkyl;  and salts thereof.   3. a compound according to claim 1 of the formula (iii): emi50.1        characterised in that:  r1 is as defined in claim 1  rú2 is hydrogen, methyl or ethyl; and  rê4 is a group of the formula:  lú - o - rê10  in which  lú is a c4-8 alkylene group,  and  rê10 is c1-2 alkyl;  and salts thereof.   4. 1-(6'-carboxyhexyl)-2-(4",4"-dimethyl-3"-hydroxy-8"-methoxyoctyl)  4-methyl-1,2,4-triazolidine-3,5-dione.      g.    a   compound    according to claim 1 of formula (iv): emi50.2       characterised in that: y, r1 and r5 are as deined in claim 1; n is 2, 3 or 4;   rú2 is hydrogen, methyl ethyl or phenyl; and r 4 is a group of formula (v): emi51.1        wherein:  l is as defined in claim 2 and v, w and z are each  hydrogen or fluorine, chlorine or bromine atoms, or cf3,  methyl, ethyl, n- or iso-propyl, methoxy, ethoxy, n- or  :iso-propoxy or nitro groups; and salts thereof.   6. 1-(6'-carboxyhexyl)-2-(3"-hydroxy-3"-methyl-4"-phenoxybutyl)  4-methyl-1,2,4-triazolidine-3,5-dione.   7. a compound according to claim 1 of formula   (vi):    emi51.2        baracterised in that:  y, nú, r1, rú2 and r5 are as defined in claim 1; and r44 is a  group of the formula  - l - qú - r 10  in which  l is as defined in formula (i);  q is a -ch=ch- group or a   -cc-    group;  r310 is c1-4alkyl, or if   q    is a   -ce=ch-    group, then   r310     may be a hydrogen atom; and salts thereof.   8. a compound according to claim 1 of formula (vii): emi51.3          characterised in that:    r1    is as defiled in claim 1;  rú2 is hydrogen, methyl or ethyl;  r54 is a group of the formula  l  - qú - r410  in which  l  is a c1-4 alkylene group    q1is    a group -ch=ch- or a group   -cc-;        is is c. alkyl or may be hydrogen if q1 is a -ch=ch- group;  10     and salts thereof.   9. 1-(6'-carboxyhexyl)-2-(4",4"-dimethyl-3"-hydroxyhept-6"-enyl)    #-methyl-1,2,4-triazolidine-3,5-dione.      10. a compound according to claim 1 of formula (viii): emi52.1       characterised in that: 1, r1 and r5 are as defined in claim 1; n is 2, 3 or rú is hydrogen, methyl, ethyl or phenyl; r64 is a group of formula (ix): emi52.2       wherein: l and q are as defined in formula (vi); and v, w and z are each   hydrogen,    chlorine or bromine atoms, or cf3, methyl, ethyl, n- or   iso-    propoxy or nitro groups, and   salts    thereof.     11. a pharmaceutical composition characterised in that it comprises  a compound of the formula (i) as defined in claim 1 and a  pharmaceutically acceptable carrier.   12. a process for the preparation of a compound of the formula (i)  as defined in claim 1, characterised by either  a) reacting a compound of formula (x): emi53.1       wherein: r2, r3, r4 and   r5    are as defined in claim 1, with a compound of formula   (xi):      t-ch2-y-(ch2)nc02r1    (xi) wherein t is a good leaving group, and y, n and r1 are as defined in claim 1.    b) reacting a compound of the formula   (xii):    emi53.2       wherein: y, n,   r1,    r4 and r5 are as defined in claim 1; with a reducing agent to give a corresponding compound of the formula (i) wherein r2 is hydrogen and r3 is hydroxy, or with a   c14    alkyl or phenyl, grignard reagent or   c14    alkyl or phenyl metallic complex to give a corresponding compound of the formula (i) wherein r2 is c1-4 alkyl or phenyl, and   r    is hydroxy; and then optionally protecting,the r3 hydroxy moiety, or c) when r5 in the compound of formula (i) is not a hydrogen atom, reacting a compound of the formula (xiii)   emi54.1       wherein: y, n, r1 and r5 are as defined inclaim 1, with a compound of formula (xiv): emi54.2       wherein the variables are as defined in claim 1.  
</CLAIMS>
</TEXT>
</DOC>
